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A B S T R A C T The ability of peripheral blood lympho-
cytes to respond to phytohemagglutinin (PHA) in vitro
was studied in patients with Down's syndrome. The re-
sponse was measured by the increase in DNA poly-
merase activity and the rate of incorporation of tritiated
thymidine by the cultured lymphocytes. These activities
were significantly lower in PHA-stimulated lymphocytes
from patients with Down's syndrome compared with
age- and sex-matched, mentally retarded patients with-
out Down's syndrome from the same institution and the
normal healthy volunteers. The impairment in response
to PHA does not seem to be related to the presence of
Australia antigen in patients with Down's syndrome or
to institutionalization itself. In contrast to DNA poly-
merase activity and thymidine-2H uptake, there was no
significant difference in the percentage of blast trans-
formation in the three groups studied. The poor re-
sponse of the lymphocytes from patients with Down's
syndrome to a mitogenic stimulus could reflect an im-
pairment of cellular immune functions in these patients
which may be one of the factors contributing to the vul-
nerability of these patients to repeated or persistent
infections.
INTRODUCTION
Impairment of immunologic defenses in patients with
Down's syndrome can be inferred from a number of
clinical and epidemiological studies. Several authors
have reported increased susceptibility of these patients
to infections, particularly those of the respiratory tract
(1-3). Institutionalized patients with Down's syndrome
also have a high frequency of Australia antigen associ-
ated with chronic anicteric hepatitis (4). Furthermore,
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these patients have been shown to have a high prevalence
of thyroid autoantibodies (5, 6) and a much higher risk
of developing leukemia than those in the general popu-
lation (7, 8). It is possible that defects in the immune
shield may not only make these patients vulnerable to
infectious agents but to allergens and carcinogens as
well. Although there is evidence of immune deficiencies
in patients with solid tissue tumors and leukemia, there
is no direct evidence that abnormal immune respon-
siveness precedes the development of these malignancies
(9, 10). The high susceptibility of patients with Down's
syndrome to leukemia is of particular significance, since
it provides an opportunity to study immunological func-
tions before the onset of clinical leukemia in a well de-
fined group.
The in vitro lymphocyte stimulation test has been used
by several workers to evaluate cellular immunity (11,
12). The ability of lymphocytes to respond to a mitogen
is commonly measured by observing the morphological
transformation of these cells into large blast-like cells
(blastogenesis) and by measuring the amount of radio-
active thymidine incorporated into cellular DNA by
these cells. We recently reported that addition of phyto-
hemagglutinin (PHA) to cultures of human peripheral
lymphocytes results in a 30- to 100-fold increase in DNA
polymerase activity and that it could be a more reliable
parameter of mitogenic response (13). In the present
study we have examined the utility of this parameter
along with the measurement of radioactive thymidine in-
corporation and cytological observations to monitor the
lymphocyte stimulation. Results from the patients with
Down's syndrome are compared with those from other
mentally retarded patients without Down's syndrome
and from normal controls. The findings are discussed
in relation to the presence of Australia antigen in pa-
tients with Down's syndrome, other immunological func-
tions and genetic constitution of these patients.
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METHODS
Selection of patients. The studies were carried out on
lymphocytes from 12 patients with Down's syndrome (2
females, 10 males) from Pennhurst State School and Hos-
pital, Spring City, Pa. Six of these patients had Australia
antigen in their peripheral blood, and six did not. The diag-
nosis of Down's syndrome was confirmed by karyotype
analysis; all the patients had trisomy of the G group.
Simultaneously, studies were done on lymphocytes from six
mentally retarded children without Down's syndrome from
the same institution (one female, five males) and six nor-
mal healthy volunteers from our staff. All six mentally
retarded patients without Down's syndrome were karyo-
typically normal. Written permission was obtained from the
parents of all mentally retarded patients for these studies.
All persons were carefully age and sex matched. The age
range of patients with Down's syndrome was between 14
and 22 yr, with a mean of 17.6 yr. The ages of other men-
tally retarded patients without Down's syndrome ranged
from 16 to 18 yr, with a mean of 17.1 yr; the normal con-
trols were between 18 and 22 yr of age.
In addition to these matched and planned groups, four
patients with Down's syndrome showing varying degrees of
mosaicism in peripheral blood and one patient with Down's
syndrome having D/G translocation [46, XY, D-, G =
t(DqGq) +], have also been studied. Both parents of the
child with translocation were also studied. The mother of
the child is the translocation carrrier.
Clinical and laboratory studies. All the patients were ad-
mitted to our Clinical Research Unit. Clinical evaluation
emphasized the history of past infections, immunizations,
and evidence of present infection. Laboratory examination
included total blood counts and serum protein electrophoresis.
Quantitative determination of immunoglobulin levels was
carried out by single radial diffusion in agar plates (Hyland
Laboratories, Los Angeles, Calif). Incubation was for 16 hr
at 250C for determination of IgA and IgM. IgG was de-
termined after incubating 4 hr at 37'C. Serum from all
persons was tested for the Australia antigen by the micro-
Ouchterlony technique. Cutaneous sensitivity was tested to
the following antigens: 0.1 ml of mumps antigen (Eli Lilly
& Co., Indianapolis, Ind.), 0.1 ml of Schick's antigen
(Wyeth Laboratories, Marietta, Pa.), 0.1 ml of intermediate
strength P.P.D.' (Merck Sharp & Dohme, West Point, Pa.),
0.1 ml of histoplasmin (Parke, Davis & Company, Detroit,
Mich.), 0.05 ml of Dermatophytin "O" (fungus extract of
Oidiomycin [Candida albicans] from Hollister-Stier Labora-
tories, Yeadon, Pa.), 0.05 ml of Trichophytin (Hollister-
Stier Laboratories), and 0.1 ml of streptokinase-strepto-
dornase-varidase (Lederle Laboratories, Pearl River, N. Y.).
The stated amounts of antigens were injected intradermally,
and at 24, 48, and 72 hr the degree of erythema and in-
duration at the site of injection was measured. Only an in-
duration of 5 X 5 mm or greater persistent at 72 hr was
scored as a positive reaction.
Preparation of lymphocyte cultures. Lymphocytes were
obtained from 50 ml of heparinized (50 U/ml) venous blood
by the method of Bach and Hirschorn (14). The final prepa-
ration of lymphocytes was suspended at a concentration of
7.5 X 10' cells/ml in Eagle's MEM (Spinner modification)
(GIBCO, Grand Island, N. Y.), with 20% fetal calf se-
rum, 1%o 1-glutamine, penicillin (100 U/ml), and streptomy-
cin (100 ,g/ml). 2-ml portions of the cell suspension were
incubated with 0.05 ml of PHA-M (General Biochemical
'P.P.D. = tuberculin-purified protein derivative.
Div., North American Mogul Products Co., Chagrin Falls,
Ohio, lot No. 685,291) in 15 ml Corex test tubes at 370C
for 3 days. All reagents used in this study were from the
same lot.
Incorporation of thymidine. 2 hr before harvesting of the
cultured cells, 5.0 Ac of methyl thymidine-2H (Schwarz Bio-
Research, Orangeburg, N. Y., 11 Ci/mmole) was added to
each culture. Incorporation of labeled thymidine was termi-
nated by adding 10 Amoles of unlabeled thymidine to each
culture and placing the cultures in an ice-water bath. The
cells were then washed by centrifugation for 10 min at 2500 g
with 0.15 M potassium chloride. To the final pellet was added
1 ml of a solution made up of 20% (w/v) glycerol (Mathe-
son, Coleman & Bell, East Rutherford, N. J., Spectroquality
grade), 0.02 M potassium phosphate buffer (pH 7.4), 0.001 M
potassium EDTA and 0.004 M reduced glutathione. There-
after the cells were disrupted by alternate rapid freezing
and thawing. The amount of radioactivity incorporated into
acid-insoluble material was determined along with the as-
say of DNA polymerase activity.
Assay of DNA polymerase activity. The assay for DNA
polymerase activity measures the incorporation of an ap-
propriately labeled deoxynucleotide into an acid-insoluble
product. The reaction mixture in a total volume of 0.3 ml,
is the following: 25 Amoles Tris (hydroxymethyl) amino-
methane-maleate buffer, pH 8.0; 3 /Amoles magnesium chlo-
ride; 1 Amole potassium chloride; 0.3 Amoles 8-mercapto-
ethanol; 25 msmoles each of dATP, dCTP, dGTP, (Cali-
fornia Foundation for Biochemical Research, Los Angeles),
and 10 m/umoles of a-32P-dTTP (about 5 X 10' dpm/mamole)(International Chemical & Nuclear Corp., City of Industry,
Calif.) ; 266 mgumoles of "activated" calf thymus DNA and
0.1 ml of the lymphocyte preparation (13).
Incubation was for 1 hr at 37°C and the reaction was
stopped by adding 0.5 ml of cold 1 M perchloric acid contain-
ing 0.01 M sodium pyrophosphate. With each set of reaction
mixtures a known amount of purified sea urchin nuclear
DNA polymerase was assayed simultaneously. The acid-
insoluble material was collected on glass-fiber filters (15).
Radioactivity was determined by standard dual labeling
techniques using liquid scintillation spectroscopy.
Assay of morphological transformation. Cytological analy-
sis was carried out in separate simultaneous lymphocyte
cultures. Cell viability was determined by the Trypan Blue
dye exclusion technique (16). The extent of blast trans-
formation and mitosis was determined by adding 0.1 ml of
Velban 2 (0.5 ttg/ml) to designated 2 ml cultures. 2 hr
later the cells were fixed in acetic-methanol (1: 3) and air-
dried preparations (17) were stained with Giemsa. From
each culture, a total of 1000 cells were counted and grouped
into small lymphocytes, lymphoblasts, and cells in mitosis.
RESULTS
The study was designed to evaluate lymphocyte function
in patients with Down's syndrome and to ascertain
whether there is any relationship with the presence of
Australia antigen, Au (1), in these patients. Our pre-
liminary observations showed that, even in normal
healthy volunteers, there might be considerable day-to-
day variation in the response of lymphocytes to phyto-
hemagglutinin. For this reason the tests were carried
out on age- and sex-matched pairs and the results were
2 Eli Lilly & Co., Indianapolis, Ind.
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statistically evaluated with the use of Wilcoxon's
matched-pairs signed-ranks test (18). The total study
included six age- and sex-matched quartets. Each
quartet consisted of a patient with Down's syndrome
with Australia antigen, a patient with Down's syndrome
without Australia antigen, a mentally retarded patient
without Down's syndrome from the same institution, and
a normal healthy volunteer. The lymphocytes from each
patient were cultured in triplicate in the presence of
PHA. Determinations of DNA polymerase activity and
thymidine uptake in the triplicate assays were in fair
agreement (±+10%). The experiment on each quartet
was repeated at least once on another day in order to
test whether the differences were in the same direction.
The results of each quartet were sequentially analyzed
(19) to decide when to stop the study.
Optimum concentration of PHA. The lymphocytes
from a quartet were cultured with different concentra-
tions of PHA. The response of a normal healthy vol-
unteer and a patient with Down's syndrome, as a func-
tion of the amount of PHA added to the culture, is shown
in Table I. The amount of PHA routinely used is desig-
nated as 1 X which corresponds to 50 Ag/1.5 X 106
lymphocytes in a 2 ml culture. The response to 1 X and
2 X concentrations is essentially the same both in the
normal individual and in the patient with Down's syn-
drome, except that the DNA polymerase activity is
higher with 1 X concentration in cultures from the nor-
mal person. In contrast, the lower concentrations (1: 10
and 1: 25) and the higher concentration (5 X) evoked
significantly lower responses than those obtained with
1 X concentration. There was no detectable response to
1: 100 and 1: 50 concentrations of PHA in all four mem-
bers of the quartet. We did not find any differences in the
TABLE I
Effect of Different Amounts of PHA on
Lymphocyte Transformation
DNA polymerase activity Thymidine-'H uptake
Down's Down's
PHA concn Normal syndrome Normal syndrome
mpmoles dTM32P/hr cMm/O. I ml
per 0.1 ml
1:25 0.002 0.009 117 167
1:10 0.018 0.016 1183 318
1 X 0.091 0.052 8968 4313
2 X 0.066 0.060 9089 4284
5 X 0.028 0.021 4726 1756
DNA polymerase activity and incorporation of thymidine
were determined as given in Methods. The standard concentra-
tion of PHA (1 X) corresponds to 0.05 ml/culture. Dilutions
were made in distilled water. 2 X and 5 X refer to 0.1 and 0.25
ml of standard PHA solution.
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FIGURE 1 Cultures of human peripheral lymphocytes were
obtained from the patients indicated. The cultures were
terminated on the days indicated and DNA polymerase ac-
tivity was assayed as given in Methods.
optimal concentrations of PHA in the different groups,
with DNA polymerase activity and thymidine incorpora-
tion as the parameters of the mitogenic response to
PHA. Therefore, in all our studies we have used the
designated 1 X concentration of the PHA-M.
Duration of incubation of cultures. Differences in
response at any given point may be due to differences in
the kinetics of the in vitro response in different cul-
tures. For this reason cultures from a quartet were in-
cubated at 37'C for different lengths of time. In one ex-
periment the cultures were harvested on days 1, 2, and
3 and in another experiment on days 2, 3, and 4. The
results are shown in Fig. 1. It is evident that the largest
increase in DNA polymerase activity was obtained after
3 days in culture in all the members of the quartet.
Similar results were obtained for the ability of the cells
to incorporate labeled thymidine into DNA. All studies
were therefore carried out on cultures incubated for
3 days at 37'C.
Impairment of lymphocyte stimulation in Down's syn-
drome. A direct comparison of the ability of lympho-
cytes to respond to PHA between patients with Down's
syndrome and age- and sex-matched normal volunteers
shows a significantly lower stimulation of DNA poly-
merase activity in Down's syndrome. In all but 4 of
the 30 comparisons on 12 pairs, the response was higher
in the normal controls (Table II, compare columns 3
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and 4 with column 1). A sequential analysis (19) of
these results is shown in Fig. 2a; the response of lym-
phocytes to PHA stimulation is greater in normal con-
trols. Analysis by Wilcoxon's matched-pairs signed-
ranks test gives a P value of < 0.001. The ability of the
same cultures to incorporate thymidine into DNA was
also determined and might be considered either a re-
lated or possibly an independent parameter of lympho-
cyte transformation. The results are nearly identical;
there is a much lower incorporation of thymidine in
cultures of lymphocytes obtained from patients with
Down's syndrome (Table III, compare columns 3 and
4 with column 1). In 30 comparisons the values in the
normals were higher than in patients with Down's syn-
drome in all except six cases. P value by Wilcoxon's
matched-pairs signed-ranks test is 0.02. In contrast to
these biochemical determinants, simultaneous cytological
analysis of the cultures revealed no significant difference
(P > 0.05) in the per cent of lymphocytes transformed
TABLE I I
DNA Polymerase Activity
Exp.
No. Normal NDMR* DS(Aui)t DS(Auo)§
Residues of dTMnP incorporated memoles/hr per 0.1 ml
1 0.101 0.241 0.005 0.049
I 2 0.167 0.151 0.009 0.033
3 0.091 0.185 0.006 0.052
II 1 0.117 0.172 0.152 0.0322 0.105 0.138 0.062 0.057
1 0.097 0.054 0.004 0.005
2 0.091 0.068 0.043 0.029
IV 1 0.093 0.029 0.010 0.004
2 0.051 0.005 0.007 0.015
1 0.086 0.036 0.028
V 2 0.031 0.009 0.027
3 0.019 0.041 0.142 0.066
1 0.145 0.164 0.041 0.030
VI 2 0.217 0.071 0.121 0.008
3 0.094 0.261 0.056 0.114
Lymphocytes from four age- and sex-matched patients were
cultured simultaneously. Six such quartets (I-VI) were
studied. Only the highest of the three values from a set of
triplicate cultures from each experiment is given. Experiments
on quartets II, III, and IV were repeated once and on quartets
I, V, and VI were repeated twice on separate days.
* NDMR: mentally retarded patient without Down's
syndrome.
t DS(Au1): patient with Down's syndrome having Australia
antigen.
§ DS(Auo): patient with Down's syndrome without Australia
antigen in his serum.
TABLE I I I
Thymidine-sH Uptake
Exp.
No. Normal NDMR* DS(Aui)l DS(Auo)§
cpm/O.1 ml
1 7,696 11,265 360 3,079
I 2 13,461 13,095 1,347 9,619
3 11,542 7,918 293 5,401
1 9,543 10,339 9,772 1,873
2 7,911 11,756 10,390 6,353
1 11,989 10,804 189 729
2 9,543 10,704 3,421 2,574
IV 1 12,100 4,603 856 848IV 2 5,156 1,379 536 1,457
1 5,500 - 1,357 801
V 2 1,538 717 5,039
3 2,748 4,395 7,007 4,221
1 11,881 6,610 4,507 5,206
VI 2 6,389 8,608 1,018 6,006
3 4,215 9,733 4,260 5,770
* NDMR: mentally retarded patient without Down's
syndrome.
I DS(Aul): patient with Down's syndrome having Australia
antigen.
§ DS(Auo): patient with Down's syndrome without Australia
antigen in his serum.
from patients with Down's syndrome and from the nor-
mal controls (see Table IV).
Comparison with other mentally retarded children.
In order to evaluate the possible contribution of host
and environmental factors on the extent of lymphocyte
stimulation in patients with Down's syndrome, age- and
sex-matched mentally retarded patients without Down's
syndrome from the same institution were included in
each experimental quartet. Results of the DNA poly-
merase activity are shown in Table II (compare columns
3 and 4 with column 2) and the extent of thymidine in-
corporation is shown in Table III (compare columns 3
and 4 with column 2). There is significantly lower DNA
polymerase activity (P < 0.001) and thymidine incor-
poration (P < 0.001) in cultures from patients with
Down's syndrome than in cultures from mentally retarded
patients without Down's syndrome. Sequential analysis
of the results is shown in Fig. 2 c. Here again the re-
sponse to PHA in mentally retarded patients without
Down's syndrome is greater than in Down's syndrome.
The results are similar to the ones obtained by compari-
son of the patients with Down's syndrome to normal
healthy volunteers. Furthermore, there is no significant
difference between mentally retarded patients without
Down's syndrome and the normal controls (P > 0.05).
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This shows that the institutionalization per se is not re-
sponsible for the differences in lymphocyte stimulation as
seen in patients with Down's syndrome (Fig. 2 b).
Australia antigen and patients with Down's syndrome.
The association of Australia antigen with hepatitis (20)
and its persistence in some patients with Down's syn-
drome can be used to study the possible relationship be-
tween lymphocyte stimulation and the presence of
chronic hepatitis. When the level of DNA polymerase
activity and the uptake of thymidine are considered in
Normals (A) compared with
patients with Down's syn-
drome (B)
Mentally retarded patients
without Down's syndrome
(A) compared with patients
with Down's syndrome (B)
relation to the presence or absence of Australia antigen
in patients with Down's syndrome (compare columns
3 and 4 in Tables II and III), we do not find any sig-
nificant differences. P values for both, by Wilcoxon's
matched-pairs signed-ranks test, are > 0.05. The data
are insufficient for a definite answer by sequential analy-
sis but the trend suggests that there is no difference
between the two groups (Fig. 2 d).
Relationship of lymphocyte stimulation to immuno-
globulin levels. Total proteins, gamma globulins and
Normals (A) compared with
mentally retarded patients
without Down's syndrome
(B)
Patients with Down's syn-
drome having Australia anti-
gen (A) compared with pa-
tients with Down's syndrome
without Australia antigen
(B)
FIGURE 2. Results of sequential analysis based on pair differences (19).
Significance probability a= 0.05. Lymphocytes from both the members
of the pair (designated A and B as above) were cultured in presence of
PHA simultaneously and assayed for DNA polymerase activity. If the
activity in A was higher than B, a cross was made immediately above
the black square in the chart. If the activity in B was higher than A, a
cross was made in the square immediately to the right of the black
square. If there is no difference, no entry is made. A second test was
made in exactly the same way and the result was entered in the square
above or to the right of that marked in the first test and so on for suc-
cessive tests. Results of repeat experiments on the same group are also
plotted separately each time. As soon as the barrier is overstepped one
of the following decisions is indicated: (1) upper barrier (U) over-
stepped, response in A is higher than in B; (2) lower barrier (L) over-
stepped, response in B is higher than in A; (3) middle barrier (M)
overstepped, no difference demonstrated.
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TABLE IV
Lymphoblast Transformation
Per cent lymphoblast transformation
Exp. Normal NDMR* DS(Aui)j DS(Auo)§
I 66 52 48 54
II 57 45 67 43
III 62 79 74 59
IV 58 70 68
V 48 52 85 63
VI 87 85 91 66
* NDMR: mentally retarded patient without Down's
syndrome.
t DS(Auj): patient with Down's syndrome having Australia
antigen.
§ DS(Auo): patient with Down's syndrome without Australia
antigen in his serum.
amounts of IgA, IgG, and IgM were determined in
serum from all patients with Down's syndrome and
mentally retarded patients without Down's syndrome.
The results are shown in Table V. There are no sig-
nificant differences in total serum proteins, gamma globu-
lins, IgA, and IgG levels between the two groups of
patients (P > 0.05). However, the IgM values are
significantly lower in patients with Down's syndrome
compared with mentally retarded patients without Down's
syndrome (P < 0.01). In order to find any correlation
between the lymphocyte stimulation and specific immuno-
globulin levels, we have calculated correlation coeffi-
cients (r values). The results are given in Table VI. A
TABLE VI
Correlation of Parameters of Lymphocyte Stimulation
with Immunoglobulin Levels
Correlation coefficients (r value)
IgA IgG IgM
DNA polymerase
activity 0.36 -0.03 0.30
Thymidine uptake 0.32 -0.01 0.47
The r values for IgM and thymidine uptake are significant at
the 0.05 level, but not for the other comparisons.
positive correlation coefficient is found for IgA and IgM
with the parameters of lymphocyte stimulation. However,
the values are not statistically significant (P > 0.05) ex-
cept for thymidine uptake and IgM levels (P < 0.05).
Skin tests. Delayed cutaneous hypersensitivity was
tested for the antigens listed in the methods section.
6 of the 12 patients with Down's syndrome did not
react to any of the antigens while only one of the five
mentally retarded patients without Down's syndrome
did not react. There was no distinct pattern of reactivity
to different antigens in the two groups. As most patients
reacted to one or two antigens only, our data are not
sufficient to determine the correlation between skin re-
activity and lymphocyte stimulation.
Results of studies on other patients. In one patient
with Down's syndrome with D/G translocation the re-
sponse to PHA stimulation was significantly lower than
that in the normal control. These findings are similar to
those seen in other trisomic mongols. The mother of
TABLE V
Serum Proteins and Immunoglobulin Levels in Patients with Down's Syndrome as Compared with
Mentally Retarded Patients without Down's Syndrome
Mentally retarded patients without Down's syndrome Patients with Down's syndrome
Total Total
Exp. proteins 7-globulins IgA IgG IgM proteins y-globulins IgA IgG IgM
g/lOO ml gilOO ml mg/lOO ml glOO ml gilOO ml mg/100 ml
I 7.7 2.17 450 1730 370 7.3 1.77 290 2250 100
7.1 1.34 570 2100 165
II 8.2 1.35 700 2000 200 7.2 1.51 340 900 90
8.4 1.57 300 1500 90
III 7.7 1.34 240 1500 175 7.1 0.79 180 850 54
8.6 2.27 220 1900 75
IV 9.2 1.56 150 1550 320 7.3 1.35 65 1000 200
7.8 1.29 390 1200 100
V 7.5 2.02 210 1650 165 8.0 1.92 340 950 62
8.3 1.65 390 1850 40
VI 7.3 1.55 125 800 220 8.3 1.42 205 1250 65
8.3 1.31 205 900 120
Total gamma-globulins determined by electrophoresis. IgA, IgG, and IgM determined by single radial diffusion technique.
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TABLE VI I
Response of Lymphocytes to PHA from a Patient with
Down's Syndrome with DIG Translocation
and His Parents
DNA polymerase
activity Thymidine uptake
dTMnP mgmoles/hr cpm/O.lml
per 0.1 ml
Normal 0.073 410.006 5590 ±539
Patient 0.010 ±0.015 698 ±992
Mother* 0.009 40.004 719 4288
Father 0.070 +0.011 2891 ±785
* Mother of the patient is a translocation carrier.
this patient is the carrier of the trait and she had a
similarly low response whereas the response in the father
was normal (Table VII). In contrast, in four patients
with Down's syndrome with varying degrees of mosaic-
ism in peripheral blood the degree of stimulation of DNA
polymerase activity and thymidine uptake were essen-
tially the same as in normal controls.
DISCUSSION
This study shows that the lymphocytes of patients with
Down's syndrome are markedly unresponsive to PHA
stimulation in vitro as compared with normals and other
mentally retarded patients without Down's syndrome.
Statistically, these differences are highly significant.
This unresponsiveness does not appear to be a function
of the concentration of PHA or the duration of incuba-
tion of the cultures up to 4 days. PHA agglutinates
lymphocytes from patients with Down's syndrome as
effectively as those from the normals. We have not found
any differences in the viability of cells in culture at
66 hr as determined by Trypan Blue dye exclusion tech-
-nique. Impairment of the lymphocyte response does not
appear to be mediated by the patients' serum since the
lymphocytes were washed twice before culturing. Also,
the comparison with mentally retarded children without
Down's syndrome from the same institution indicates
that the impairment of lymphocyte stimulation in pa-
tients with Down's syndrome is not due to a nonspecific
environmental factor prevalent in the institution. For
these reasons the impaired responsiveness seems to be
an innate characteristic of the lymphocytes of patients
with Down's syndrome.
In the present study we did not find a correlation be-
tween the morphological changes and the rate of thymi-
dine-3H incorporation in PHA-stimulated lymphocytes
from patients with Down's syndrome. While the thy-
midine uptake by the lymphocytes from patients with
Down's syndrome was significantly lower than those
from normals, there was no difference in the percentage
of lymphoblast transformation. This can be taken to in-
dicate that simultaneous DNA synthesis is not essential
for the appearance of morphological changes. Recently,
Kay, Levanthal, and Cooper (21) reported that lympho-
cytes cultured in the presence of actinomycin D which
prevents DNA synthesis and mitosis, exhibit -typical
cytological changes indicative of blastogenesis. Our un-
published observations support their findings. However,
the rate of thymidine incorporation may be subject to
fluctuations in the concentrations of metabolites within
the cell as well as by the activities of the enzymes on the
"salvage pathway" by which the external thymidine is
incorporated into cellular DNA. In this regard a simul-
taneous assay of the DNA polymerase activity on the
same cultures may not only provide a confirmatory evi-
dence for the validity of thymidine uptake results but
may also provide a more reliable parameter to evaluate
the true mitogenic response. The addition of PHA to
cultures of human lymphocytes results in a marked in-
crease in DNA polymerase activity which is closely re-
lated temporally and in magnitude to thymidine incor-
poration into cellular DNA by the same cultures (13).
The activity of the enzyme is assayed in vitro using the
cell lysate and known concentrations of substrates. The
sensitivity of the assay is only limited by the specific
activity of the radioactive precursor. Further the two
parameters are independent measurements of the ability
of the cells to synthesize DNA. In the present study the
DNA polymerase activity and thymidine uptake mea-
surements run parallel in all the lymphocyte cultures
from patients with Down's syndrome. Thus the lympho-
cytes from patients with Down's syndrome are truly
hyporesponsive to the mitogenic stimulus of PHA. This
disparity between the morphological changes and bio-
chemical events following the PHA stimulation of lym-
phocytes from patients with Down's syndrome may ex-
plain the differences in our results from those reported
by Hayakawa, Matsui, Higurashi, and Kabayashi (22)
and Sasaki and Obara (23).
The immune status of patients with Down's syndrome
has not been systematically studied. Donner (2) found
a significantly lower number of tuberculin-positive in-
dividuals among patients with Down's syndrome com-
pared with other children from the same locales. How-
ever, vaccination with Calmette-Guerin bacillus (BCG)
evoked a similar response in patients with Down's syn-
drome and normal controls. Impairment of antibody
formation and functions has not been conclusively dem-
onstrated. The total amount of gamma globulin appears
to be increased (24, 25). Sutnick, London, and Blum-
berg (26) have reported a lower level of immunoglobu-
lin M in outpatients with Down's syndrome. In the pres-
ent study also, the immunoglobulin M levels are sig-
nificantly lower in patients with Down's syndrome as
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compared to mentally retarded children without Down's
syndrome from the same institution and there is a posi-
tive correlation between lymphocyte stimulation and IgM
levels. The biological significance of this correlation is
not known. Conflicting results have been reported as to
the ability of patients with Down's syndrome to pro-
duce specific antibodies after activity immunization (27,
28). In view of the uncertainties about defects in the
humoral antibody in patients with Down's syndrome,
the impairment of lymphocyte stimulation could be par-
ticularly germane to the clinical observations.
The essential role of circulating lymphocytes in im-
mune responses is well documented (29). PHA-induced
in vitro lymphocyte stimulation has been used to assess
the immune capabilities of these cells (11, 12, 30, 31).
When lymphocytes are cultured in the presence of PHA
there is a sequential stimulation of RNA, protein, and
DNA synthesis. Simultaneously these cells also undergo
morphologic changes resulting in large cells with promi-
nent nucleoli and intensely basophilic cytoplasm. Cells
of similar appearance are observed in the regional
lymph nodes after in vivo immunization (32). Changes
similar to those that occur on PHA stimulation are ob-
served on stimulating lymphocytes with antigens to
which a person is known to have been sensitized previ-
ously (33, 34) and in mixed leukocyte reactions where
histocompatibility antigens appear to be the stimulating
factors (14). PHA-treated lymphocytes have been
shOwn to synthesize immunoglobulins (35-37), specific
antibodies (36, 37), and interferon (38). PHA-stimu-
lated cells are also capable of destroying human fibro-
blasts in vitro (39). In a number of diseases in which
immune deficiency is present an impairment in PHA
stimulation of lymphocytes has been reported (for ref-
erences, see 12). Thus it is reasonable to assume that
impaired in vitro lymphocyte stimulation in patients
with Down's syndrome reflects an impairment in cellular
defenses which could contribute to their enhanced vul-
nerability to pathogens.
In other studies we have shown a high incidence
of Australia antigen, a particle of 200 A in diameter,
associated with chronic anicteric hepatitis in institu-
tionalized patients with Down's syndrome (4). Willems,
Melnick, and Rawls (40) have reported impaired re-
sponse to PHA stimulation in lymphocytes from pa-
tients with infectious hepatitis. The presence of a virus
in these cells could be responsible for the impairment in
the response to a mitogenic stimulus as has been shown
by Olson et al. (41) and Willems et al. (40). How-
ever, in this study a comparison of the extent of im-
paired lymphocyte stimulation in groups with Down's
syndrome with and without Australia antigen revealed no
significant differences. However, the precipitin test
used for detection of the Australia antigen may not be
sensitive enough to detect all persons with Australia
antigen.
The induction of replication may also be dependent on
the genetic constitution of the cells. Kamin, Fudenberg,
and Douglas (42) have reported impaired in vitro lym-
phocyte transformation in the asymptomatic parents of
patients with "acquired" agammaglobulinemia. Although
the exact role of an extra chromosome in the mani-
festations of Down's syndrome is not understood at pres-
ent, it is beyond question that a definite genetic ab-
normality including a gross chromosomal error exists
in these patients. In one translocation mongol (D/G) we
have seen impairment in lymphocyte stimulation simi-
lar to that observed in mongols with simple G group
trisomy. In contrast, the lymphocytes from four patients
with Down's syndrome having varying degrees of
mosaicism in the peripheral blood responded to PHA
stimulation as did the normal controls. However, im-
paired lymphocyte stimulation to PHA in patients
with Down's syndrome may not be a simple attribute
of extra chromosomal material. In the mother of the
translocation mongol, who is the carrier of the trait,
the lymphocytes were equally unresponsive to PHA. It
is possible that further studies in this direction may help
in understanding the effect of chromosomal aberrations
on cell replication.
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